Skip to main content

Need Immediate Care?

Find Urgent Care Locations

Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

Short Title: EA8191 (INDICATE)


Enrollment Status: Recruiting

NCT #: NCT04423211

Specialty Area: Oncology

Condition Studied: Prostatic Adenocarcinoma

Age Groups: Adult; Older Adult

Phase: III


Study Information

Summary / Purpose

The purpose of this study is to compare the usual treatment alone to the usual treatment plus additional treatment for patients with prostatic adenocarcinoma, based on the results of PET imaging that looks for cancer that has spread outside of the pelvis.

All participants in this study have had their prostate removed (a radical prostatectomy) and have a rising PSA blood level afterward, which is called biochemical recurrence. A PSMA PET scan is used to look for areas of cancer, and the results of that scan help guide which treatment options are studied.

If the PET scan finds areas of tumor outside of the pelvis (for example, metastases, or metastatic lesions), this study will look at whether treating those areas with targeted, metastasis-directed radiation affects cancer control.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

This study is open to adult and older adult men who have a rising PSA level after surgery to remove the prostate. The points below describe the main eligibility requirements. They are not the complete list.

  • Adult males 18+ years of age
  • Confirmed diagnosis of prostatic adenocarcinoma
  • Must have had a radical prostatectomy
  • Must have biochemical recurrence after radical prostatectomy
  • Must be a candidate for post-prostatectomy radiation therapy

Healthy volunteers are not enrolled in this study. The study team can review the full list of eligibility requirements with you, and the complete criteria are also listed on ClinicalTrials.gov under study NCT04423211.

What's Involved

Participation in the study will include:

Participation in this study includes imaging, assignment to a treatment option by chance (randomization), treatment, and follow-up visits with regular monitoring. What this involves may include:

  • A PET scan to see whether the cancer has spread outside the pelvis
  • Placement into a group based on PET results, then random assignment to a treatment option within that group
  • Standard radiation therapy and short-term hormone therapy, with or without apalutamide, an oral hormone-blocking medicine, for patients with no spread outside the pelvis
  • Standard radiation therapy, short-term hormone therapy, and apalutamide, with or without targeted radiation to the areas of spread, for patients with spread outside the pelvis
  • Quality-of-life questionnaires

Participants also return for follow-up visits that may include physical exams, blood tests such as PSA, and imaging. The study team will explain the schedule of visits and procedures before you decide whether to take part.

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.